Shire PLC (NASDAQ:SHPG) has received an average recommendation of “Hold” from the eighteen brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $212.10.
Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $222.00 price target on shares of Shire in a report on Thursday, September 14th. Liberum Capital reissued a “hold” rating on shares of Shire in a report on Wednesday. Royal Bank of Canada reissued a “buy” rating and issued a $213.00 price target on shares of Shire in a report on Monday, October 2nd. ValuEngine lowered shares of Shire from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $245.00 price target on shares of Shire in a report on Sunday, October 8th.
A number of large investors have recently modified their holdings of the business. Synovus Financial Corp lifted its position in Shire by 0.4% during the 2nd quarter. Synovus Financial Corp now owns 2,780 shares of the biopharmaceutical company’s stock worth $458,000 after buying an additional 11 shares in the last quarter. Baldwin Investment Management LLC grew its stake in Shire by 1.4% in the 2nd quarter. Baldwin Investment Management LLC now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after buying an additional 23 shares during the last quarter. Lumbard & Kellner LLC grew its stake in Shire by 0.3% in the 2nd quarter. Lumbard & Kellner LLC now owns 18,170 shares of the biopharmaceutical company’s stock valued at $3,003,000 after buying an additional 55 shares during the last quarter. Thompson Investment Management Inc. grew its stake in Shire by 0.7% in the 2nd quarter. Thompson Investment Management Inc. now owns 8,922 shares of the biopharmaceutical company’s stock valued at $1,475,000 after buying an additional 62 shares during the last quarter. Finally, Sequoia Financial Advisors LLC grew its stake in Shire by 4.8% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,412 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 65 shares during the last quarter. 20.19% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Shire (SHPG) traded down $4.45 during mid-day trading on Thursday, hitting $153.20. 1,678,400 shares of the stock traded hands, compared to its average volume of 1,140,200. Shire has a one year low of $137.17 and a one year high of $192.15. The firm has a market cap of $47,411.98, a price-to-earnings ratio of 10.84, a price-to-earnings-growth ratio of 0.88 and a beta of 1.59. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55.
Shire (NASDAQ:SHPG) last announced its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.64 by $0.17. Shire had a net margin of 10.95% and a return on equity of 14.41%. The company had revenue of $3.70 billion during the quarter. During the same period last year, the firm earned $3.17 EPS. Shire’s quarterly revenue was up 7.1% on a year-over-year basis. sell-side analysts predict that Shire will post 15 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://ledgergazette.com/2018/01/13/shire-plc-shpg-given-average-rating-of-hold-by-brokerages.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.